Frontiers in Oncology (Jul 2024)

Challenges in the treatment of BRAF K601E-mutated lung carcinoma: a case report of rapid response and resistance to dabrafenib and trametinib

  • Akihiro Nishiyama,
  • Shigeki Sato,
  • Hiroyuki Sakaguchi,
  • Hiroshi Kotani,
  • Kaname Yamashita,
  • Koushiro Ohtsubo,
  • Shigeki Nanjo,
  • Seiji Yano,
  • Keishi Mizuguchi,
  • Hiroko Ikeda,
  • Shinji Takeuchi

DOI
https://doi.org/10.3389/fonc.2024.1374594
Journal volume & issue
Vol. 14

Abstract

Read online

We report a case of limited effectiveness of dabrafenib and trametinib in a 59-year-old man with poorly differentiated lung carcinoma and a rare BRAF K601E mutation. The patient, unresponsive to chemotherapy and immunotherapy, received these targeted agents as second-line treatment. Despite a notable initial response, tumor regression lasted only 52 days. A subsequent liquid biopsy revealed additional alterations (BRAF amplification, KIT amplification, TP53 S241F), indicating a complex resistance mechanism. This case underscores the challenges in treating BRAF K601E-mutant lung carcinoma, emphasizing the need for advanced molecular diagnostics, personalized approaches, and further research into more effective therapies for unique genetic profiles.

Keywords